Arcus Biosciences (RCUS) Assets (2017 - 2026)

Arcus Biosciences has reported Assets for 10 years, with the latest figure at $997.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 16.92% year-over-year to $997.0 million; the trailing twelve-month figure through Mar 2026 stood at $997.0 million (down 16.92% YoY), and the FY2025 full-year result was $1.1 billion, down 0.96% from the prior year.
• Assets for Q1 2026 stood at $997.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Assets was $1.5 billion in Q1 2022, with the low at $974.0 million in Q3 2025.
• Average Assets over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Assets surged 66.07% in 2022 and declined 25.08% in 2025.
• Tracing RCUS's Assets over 5 years: stood at $1.3 billion in 2022, then fell by 15.77% to $1.1 billion in 2023, then advanced by 5.02% to $1.2 billion in 2024, then retreated by 0.96% to $1.1 billion in 2025, then declined by 12.47% to $997.0 million in 2026.
• The last three Assets figures came in at $997.0 million (Q1 2026), $1.1 billion (Q4 2025), and $974.0 million (Q3 2025), per Business Quant data.

Peer Comparison